Cargando…
Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
OBJECTIVE: The treatment of patients with differentiated thyroid cancer (DTC) was modified in the last decade towards a more individualized approach according to the risk of recurrence (RR). We compared the outcomes of patients with low and intermediate RR (LRR and IRR) who received or did not recei...
Autores principales: | Abelleira, Erika, Peñaloza, Mirna Angela, Jerkovich, Fernando, Bueno, Fernanda, Pitoia, Fabián |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065346/ https://www.ncbi.nlm.nih.gov/pubmed/34731559 http://dx.doi.org/10.20945/2359-3997000000374 |
Ejemplares similares
-
New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022) -
Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018) -
Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
por: Pitoia, Fabián, et al.
Publicado: (2012) -
Thyroid cancer in the Era of COVID-19
por: Smulever, Anabella, et al.
Publicado: (2020) -
Selective use of sorafenib in the treatment of thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2016)